Mechanistic Analysis of Chemical Permeation Enhancers for Oral Drug Delivery
Traditionally, the oral route cannot be employed for the delivery of macromolecular drugs such as proteins and peptides due, in large part, to limited transport across the epithelial membrane. This particular challenge can potentially be addressed through the use of chemical permeation enhancers, which affect transcellular and/or paracellular transport routes. Although certain permeation enhancers have been proposed for use in oral delivery, potential for application is often unclear when the route of enhancer action is unknown.
A combination of theory and experiments was developed for determining mechanism of enhancer action. The effect of 51 enhancers on Caco-2 cells was studied using TEER, MTT, and LDH assays.
The mechanistic details of intestinal permeability enhancement were uncovered for a broad set of enhancers in vitro. Understanding gained from enhancer mechanisms enabled the deduction of structure–function relationships for hydrophilic and hydrophobic permeation enhancers as well as the identification of a transcellular enhancer, 0.01% (w/v) palmityldimethyl ammonio propane sulfonate, which enabled the non-cytotoxic intracellular delivery of a model drug.
The results presented here emphasize the importance of understanding enhancer mechanism and uncover a zwitterionic surfactant capable of safely and effectively achieving intraepithelial drug delivery in vitro.
Key wordsCaco-2 mechanism oral drug delivery permeation enhancer transcellular
- Log P
Water-octanol partion coefficient
Methyl thiazole tetrazolium
Palmityldimethyl ammonio propane sulfonate
Transepithelial electrical resistance
This work was supported by a fellowship to KW from the Graduate Research and Education in Adaptive bio-Technology (GREAT) Training Program by the University of California Biotechnology Research and Education Program and by the American Diabetes Association. The authors would also like to thank Natalie Karr for technical assistance.
- 6.D. Bourdet, G. Pollack, and D. Thakker. Intestinal absorptive transport of the hydrophilic cation ranitidine: A kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm. Res. 23:1178–1187 (2006).PubMedCrossRefGoogle Scholar
- 15.T. Uchiyama, T. Sugiyama, Y. S. Quan, A. Kotani, N. Okada, T. Fujita, S. Muranishi, and A. Yamamoto. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: Their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoside. J. Pharm. Pharmacol. 51:1241–1250 (1999).PubMedCrossRefGoogle Scholar
- 26.K. Whitehead, N. Karr, and S. Mitragotri. Safe and effective enhancers for oral drug delivery. Pharm Res. in press. DOI 10.1007/s11095-007-9488-9.
- 28.B. Aspenstrom-Fagerlund, L. Ring, P. Aspenstrom, J. Tallkvist, N.-G. Ilback, and A. W. Glynn. Oleic acid and docosahexaenoic acid cause an increase in the paracellular absorption of hydrophilic compounds in an experimental model of human absorptive enterocytes. Toxicology 237:12–23 (2007).PubMedCrossRefGoogle Scholar
- 32.C. Pilette, B. Colinet, R. Kiss, S. Andre, H. Kaltner, H. J. Gabius, M. Delos, J. P. Vaerman, M. Decramer, and Y. Sibille. Increased galectin-3 expression and intraepithelial neutrophils in small airways in severe chronic obstructive pulmonary disease. Eur. Respir. J. 29:914-922 (2007). DOI 09031936.00073005.Google Scholar